Recent Updates
Recently added Catalysts
HRMY Positive Sentiment Score: 70/100

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Thursday, May 7, 2026 1 min read
Key Takeaway: Harmony Biosciences reported a Q1 2026 revenue of $215.4 million, marking a 17% year-over-year growth driven by strong demand for WAKIX®. Despite facing market access challenges, the company has reaffirmed its guidance for over $1 billion in net revenue for 2026. This follows a record performance over the last three quarters.

Market Sentiment Analysis

POSITIVE FACTORS

  • Q1 2026 revenue reached $215.4 million, a 17% increase year-over-year.
  • Strong demand for WAKIX® continues to drive growth.
  • The company has reinforced its 2026 revenue guidance of over $1 billion.

CONCERNS & RISKS

  • Market access headwinds were more pronounced this year compared to previous Q1s.

Full Press Release Details

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also

Frequently Asked Questions

What was Harmony Biosciences' Q1 2026 revenue?

Harmony Biosciences reported a Q1 2026 revenue of $215.4 million.

How much did WAKIX® revenue grow in Q1 2026?

WAKIX® revenue grew by 17% year-over-year in Q1 2026.

What is Harmony's revenue guidance for 2026?

Harmony Biosciences has confirmed a revenue guidance of over $1 billion for 2026.

What challenges did Harmony face in Q1 2026?

The company experienced more pronounced market access headwinds in Q1 2026.

Tags: HRMY Viatris Investor Conferences Healthcare WAKIX Q1 2026 revenue growth financial results
Last updated: May 7, 2026